On April 30, 2020, Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that six preclinical data presentations on its engEx™ Platform programs, of which three are oral presentations, will be presented at the 23nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT), which will be held virtually on May 12-15, 2020. In addition, Codiak’s Executive Vice President of Manufacturing and Process Sciences, Konstantin Konstantinov, PhD, will give an invited lecture on Codiak’s approach to industrial exosome manufacturing as part of the scientific symposium entitled “Advancing Therapeutic Exosomes for the Treatment of Disease,” which is being organized by the Nanoagents & Synthetic Formulations Committee. “These data presentations highlight the significant progress that we have made on our engEx Platform and its broad potential to generate new classes of molecular medicines,” said Jonathan Finn, PhD, Vice President, Discovery Research at Codiak BioSciences. “Targeted delivery is critical for drug development, and we are particularly encouraged by our data showing that we can use our engEx platform to selectively drive exosome uptake into multiple cell types both in vitro and in vivo. We are also excited to debut our data using exosomes as a novel vaccine approach, capitalizing on the unique immune response our exoVACC™ platform can generate when compared with standard vaccine platforms.” The titles and schedules for the Codiak presentations at the ASGCT annual meeting are listed below.
CODIAK ORAL PRESENTATIONS
“Induction of Potent Systemic and Tissue Resident Immune Responses by exoVACC™: a Novel Exosome-based Vaccine Platform”
Abstract number: 66
Date/Time: Tuesday May 12, 2020, at 10:45 AM ET
Login Or Register To Read Full Story